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Abstract
Introduction: A heterogeneous emphysema is one of the most severe forms of chronic obstructive pulmonary disease (COPD). 
In some cases, besides the standard pharmacotherapy, a new treatment option of emphysema can be used — bronchoscopic 
lung volume reduction (BLVR) with the use of intrabronchial valves.
Objectives: To examine the health-related quality of life (HRQoL) of patients with severe emphysema after intrabronchial valve 
(IBV) implantation for the treatment of one lung.
Materials and methods: From 2011 to 2013 a single centre prospective observational study was performed. The study assessed 
the effect of the therapeutic BLVR intervention, measured by St. George Respiratory Questionnaire (SGRQ). A statistical analysis 
by use of Wilcoxon test for dependent variables was performed.
Results: Twenty patients were enrolled to the study (mean age 63 ± 10 years), all ex-smokers with tobacco exposure 38 ± 11.3 
packyears. After three months of IBV treatment the average SGRQ score improved significantly in total (–12.8; p < 0.001) and in domains 
and the differences were for: “symptoms” (–8.5; p < 0.001), “activity” (–13.9; p < 0.001) and “influence on life”(–13.5; p < 0.002).
Conclusions: The presented study revealed a significant improvement in the quality of life measured by SGRQ after IBV treatment 
for heterogeneous emphysema.
For the first time our study showed the significant improvement of all three domains of SGRQ after IBV treatment.
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Introduction
Chronic obstructive pulmonary disease 
(COPD) is one of the most frequent chronic con-
ditions, rated as fifth the most common cause of 
death and its frequency is still increasing. COPD 
as a progressive and irreversible disease is now 
one of the most essential problems of public 
health [1, 2]. Evaluation of quality of life is very 
important for monitoring of health problems of 
patients suffering from COPD. Studies about 
quality of life are a valuable complement to the 
assessment of patients’ clinical condition and 
a clue about the effects of treatment and possible 
improvements. For several years attempts have 
been made to improve to improve the quality of 
life of patients with heterogeneous emphysema 
due to COPD involving minimally invasive me-
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thods of bronchoscopic lung volume reduction 
(BLVR) with intrabronchial valves as an alternative 
to a  lung volume reduction surgery (LVRS) and 
pharmacotherapy [3]. Previous results of treatment 
of severe emphysema, especially heterogenic, by 
LVRS seem to be more effective (reduces dyspnoea 
and increases lung function tests results) comparing 
to pharmacotherapy. However LVRS performed by 
thoracotomy is associated with high perioperative 
mortality (5%) and higher mortality caused by 
pulmonary (30%) and cardiovascular (20%) compli-
cations mainly due to prolonged (> 7 days) pleural 
drainage caused by continued air leak [3]. The aim 
of the emphysematic LVRS and BLVR treatment is 
to eliminate the emphysematic lung tissue (usually 
upper lobes). BLVR methods include: intrabron-
chial valves (IBV, Zephyr), transbronchial stents 
causing so called airway bypass [4, 5], chemical 
blockers of bronchi such as Aeroseal, thermal va-
pour ablation [6] and implants, so called coils [7]. 
Bronchoscopic techniques may also be successful-
ly used as a treatment of homogenous emphysema, 
in which surgery is not recommended [8].
The umbrella shaped valves have a framework 
constructed of six nitinol branches, covered with 
a polyurethane membrane, which causes optimal 
adhesion to the bronchial wall (Fig. 1) [9, 10]. The-
se valves ensure that there is a one-way flow of air 
discharge from the closed part of the segment or 
the lobe of the lung during expiration and protect 
from inflow of air during inspiration (Fig. 2).
The procedure is performed during video 
bronchofiberoscopy under conscious intravenous 
sedation or by use of rigid bronchoscopy under 
general anaesthesia.
Current traditional methods of health assess-
ment, which do not fulfill the holistic model of 
entire human well-being have been questioned, 
what contributed to the development of resear-
ches on patients’ quality of life with the aim of 
making it active and simliar to the life of a healthy 
Figure 1. IBV Spiration Inc., USA; Olympus Medical Systems Corpo-
ration, Tokyo, Japan
Figure 2.  Two intrabronchial valves (IBV No 7) placed in the subsegmen-
tal bronchi of the right segment 3. From the Archives of Department of 
Thoracic Surgery and Endoscopy Unit of John Paul II Hospital, Cracow
person [11]. The assessment of quality of life during 
a disease, especially chronic disease is personal 
and its measurements may be useful for doctors 
and nurses in changing therapy and care [12, 13].
The aim of this study was to compare the 
quality of life of patients suffering from severe em-
physema before and after the treatment with IBV.
Materials and methods
This prospective observational study was 
conducted as a diagnostic survey with an in-
terview technique using the standardised qu-
estionnaire from the Hospital of St. George (St. 
George Respiratory Questionnaire — SGRQ), 
which was used to compare the quality of life 
before and after the treatment of heterogeneous 
emphysema with IBV. SGRQ is at present the 
best available tool to assess the quality of life of 
patients with COPD, especially when it is conduc-
ted as an interview instead of being filled in by 
the patient [14–15]. This questionnaire contains 
50 essential questions about the quality of life of 
COPD patients concerning three aspects (symp-
toms, activity and influence on life). Every answer 
indicates an experimentally measured number 
of points, the sum of which determines a final 
result. The results range from 0 to 100, where 0 
means the highest and 100 — the lowest quality 
of life. The results of SGRQ were evaluated using 
a prepared spreadsheet.
Interviews with patients were conducted twi-
ce: the first time — 1–2 days before the procedure 
of an implantation of IBV and the second time — 3 
months after the treatment with the same tool.
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Figure 3. Comparison of a total SGRQ score before and after treatment 
with IBV using a Wilcoxon test
Inclusion criteria for IBV implantation in our 
study were comparable with those used in the 
VENT study [16, 17]. Exclusion criteria included 
active infection, unstable cardiac condition, ex-
cessive sputum or the presence of giant bullae.
A statistical analysis was conducted based 
on descriptive statistics, i.e., the arithmetic mean 
with standard deviations, median, considering 
upper and lower quartile and minimal and ma-
ximal value. To evaluate both total SGRQ and its 
separate domains a Wilcoxon matched pairs test 
for dependent variables was used.
Results
The present study was conducted in the De-
partment of Thoracic Surgery and Endoscopic Unit 
of John Paul II Hospital from October 2011 to May 
2013. Due to the innovative character of the treat-
ment of heterogeneous emphysema and the still 
very rare usage of implantation of IBV in Poland 
twenty patients suffering from heterogeneous em-
physema due to COPD were enrolled to the study.
The examined group consisted of 16 men 
and 4 women, whose age was between 40 and 81 
years, on average 63 ± 10 years and the duration 
of COPD was on average 12 ± 3years. All of the 
patients were ex-smokers and the mean tobacco 
exposure was 38 ± 11.3 packyears and ranged 
between 20 and 60 packyears. Only 4 (20%) of 
them had proven exposure to dust and chemi-
cals. Two of them were long-standing workers of 
a sawmill, exposed to wood dust, oil paints and 
carpenter’s  glues. A third patient had worked 
in a cement works for 25 years, being exposed 
to a dust of cut stone and concrete, cement and 
asbestos. Fourth patient worked in a coal mine in 
direct exposure to a coal dust.
Forced expiratory volume (FEV1) measured 
before treatment with IBV was 0.93 ± 0.53 L and 
30.87 ± 13.62% of the predicted value, total lung 
capacity (TLC) was 6.21 ± 2.43 L and 104.16 ± 
30.77% of the predicted value, residual volume 
(RV) was 4.42 ± 2.15 L and 214.49 ± 69.39% 
of the predicted value, body mass index (BMI) 
was 23.37 ± 6.07, and 6MWT distance was 110 
± 111.9 m, PaCO2 of less than 50 mm Hg and 
a PaO2 of more than 55 mm Hg (while breathing 
ambient air). 
On the basis of the total SGRQ score in the 
examined group a  significant improvement in 
the quality of life after treatment with IBV was 
observed. The mean score for this group before 
treatment was 73.0 ± 15.0, while after treatment 
is was — 60.2 ± 16.6. At least 4 points of SGRQ 
score improvement were obtained among 70% 
of patients. The mean difference between total 
SGRQ score before and after treatment with IBV 
was –12.8 ± 11.9; p < 0.001. Among 25% of pa-
tients this difference reached –28.3 ± 11.9; p < 
0.0001. The medians of scores were respectively 
75.8 before and 64.4 after treatment and –10.7 for 
the difference (Fig. 3).
The mean score in the domain “symptoms” 
of the SGRQ test before treatment with IBV was 
69.8 ± 18.0 while the mean score after treatment 
was — 61.3 ± 18.6. So after treatment a signif-
icant improvement was achieved and the mean 
difference of a score was –8.5 ± 8.5; p < 0.001. 
The medians of scores were respectively 68.0 
before and 59.8 after treatment and –7.7 for the 
difference (Fig. 4).
In this domain of the questionnaire it was 
observed that a cough during the three months be-
fore treatment appeared most frequently (among 
40% of patients) on most of the days in a week, 
whereas after treatment — most commonly (also 
among this 40% of patients) on a  few days in 
a week. A thick expectoration during the three 
months before treatment was most frequently 
(among 50% of patients) present during most days 
in a week, while after treatment — a few days in 
a week. During the three months before treat-
ment with IBV breathlessness during most days 
occurred among no less than 80% of patients and 
after treatment only among 40%. After the treat-
ment the frequency of breathlessness decreased 
to a few days in a week among 30% of patients 
and to a few days in a month among 25% of pa-
tients. Moreover it was established that during 
the 3 months before treatment dyspnea attacks 
occurred most frequently (among 40% of patients) 
during most of the days of a week, among 20% 
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Figure 4. The comparison of a domain “symptoms” SGQR score before 
and after treatment with IBV using a Wilcoxon test
Figure 5. The comparison of a domain “activity” SGQR score before 
and after treatment with IBV using a Wilcoxon test
of patients — a few days in a week and among 
20% — a few days in a month. After the treatment 
dyspnea attacks most often occurred during a few 
days of a month (35% of patients), a few days of 
o week — 20%, and for the most days of a week 
— only among 15%. Before the treatment 65% of 
patients and after treatment only 30% of them 
reported respiratory symptoms during the most 
days of a week in last 3 months. A deterioration 
of symptoms usually occurred for 1–2 days re-
gardless of performed procedure.
A mean score of the domain “activity” SGRQ 
before the treatment with IBV was 82.3 ± 16.8, 
whereas a mean score after treatment was 68.4 ± 
16.9. After the treatment a significant improve-
ment in this domain was achieved and a difference 
in score was –13.9 ± 11.8; p < 0.001. The medians 
of scores were respectively 85.8 before and 72.3 
after treatment and –12.8 for the difference (Fig. 5).
Before the treatment even a low activity such 
as sitting or lying (30%), walking in a house (50%) 
and on a flat terrain (60%) caused dyspnea. After the 
treatment these activities caused dyspnea among 
a significantly lower percentage: respectively 5%, 
35%, 15% and 25%. On the other hand high activ-
ity such as: going upstairs and uphill and exercise 
caused dyspnea among almost all patients regard-
less of whether they were treated with IBV or not.
A mean score in the domain “influence on 
life” before the treatment was 68.7 ± 17.0, while 
after the treatment — 55.2 ± 19.0. After the 
treatment a significant improvement also in this 
domain of SGRQ was obtained and the mean dif-
ference of the score was –13.5 ± 16.1; p < 0.002. 
The medians of scores were respectively 73.2 
before and 59.5 after treatment and –10.7 for the 
difference (Fig. 6).
In this domain of questionnaire as many as 
60% of patients recognized their disease as the 
biggest problem and reported that respiratory 
problems were the reason for quitting their job, 
regardless of the treatment with IBV. It is worth to 
mention that almost all examined patients were 
not professionally active (pension or retirement). 
After the treatment with IBV a percentage of pa-
tients who could not perform any wished activ-
ity due to emphysema reduced to 40%. Patients 
declared that they experienced an improvement 
of free speech (without dyspnea) (by 25%); qual-
ity of speech (by 35%), pain during cough ( by 
10%), fatigue caused by cough (by 15%) and 
general fatigue (by 10%). After the treatment 
patients regarded with higher hope their health 
(improvement by 25%), effects of treatment ( by 
35%) and a range of independence (shopping on 
their own — improvement by 20%), they were 
Figure 6. The comparison of a domain “influence on life” SGQR score 
before and after treatment with IBV using a Wilcoxon test
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not afraid to exercise (improvement by 25%) and 
entertain (improvement by 20%). Patients felt also 
higher self-control and more rarely got into a panic 
during exacerbations of the disease and overcom-
ing obstacles required less effort (improvement by 
20%). Unfortunately, despite the treatment they 
still felt weak and disabled, were embarrassed in 
the others’ presence by their symptoms, which 
patients regarded as bothersome for the people 
around them. What also did not change was a feel-
ing of breathlessness while bending (it occurred 
among 75% of patients), possibility to exercise 
and doing all the household chores. To reassume, 
the quality of life of examined patients 3 months 
after the treatment with IBV improved significantly 
both when it comes to the total SGRQ score and 
all its domains.
Discussion
For a few years in some European pulmono-
logical and thoracosurgical departments the mini-
mally invasive BLVR method using intrabronchial 
valves has been introduced [9, 18–21]. The results 
of multicentre studies conducted so far are promi-
sing, although not in all of them an improvement 
of spirometric parameters or radiological image 
was not observed in all of them [9, 10, 18, 22]. 
However, in most of studies an improvement of the 
quality of life of patients treated with BLVR method 
was noticed [9, 16, 18, 19]. The results of a few 
multicentre trials using BLVR with intrabronchial 
valves as a  treatment of severe emphysema are 
promising — they seem to be as effective as LVRS 
with significantly lower numbers of lethal and 
perioperative complications [9, 18]. Nonetheless, 
only a few trials have shown a significant impro-
vement of pulmonary function tests and 5-years 
survival after BLVR treatment [4, 21–23].
The results of a few trials indicate a signifi-
cant improvement of the quality in life of severe 
emphysema patients treated with IBV implan-
tation [14, 19]. So far no studies evaluating the 
effects of treatment with IBV based on separate 
domains of the St. George Respiratory Question-
naire (SGRQ) have been conducted.
In the research of Springmeyer et al. [9] 
an improvement in the total SGRQ score was 
observed just 3 months after implantation, but 
a significant difference by at least 4 points was 
noticed among 55.7% of patients only after 6 
months. In the study of Sterman et al. [18] a 
minimal clinically important improvement of 
SGRQ score (at least 4 points) was obtained after 
1 month among 51% of patients, after 3 months 
among 53%, after 6 months among 55% and 
after a year among 57%. Similarly, in our study 
a significant improvement of SGRQ by at least 4 
points was observed after 3 months among 65% of 
patients. In a study of Coxon et al. [22] a statisti-
cally important correlation between an improve-
ment of quality of life in SGRQ and a volume of 
the lower lobe of lung in HRCT after excluding 
from ventilation the upper lobe using IBV was 
observed. In the biggest multicentre randomized 
study Wood et al. [19] and Sciurba et al. [16] 
demonstrated a mean difference in SGRQ re-
spectively –10.7 ± 11.5 and –11.2 ± 14.3 3 
months after implantation of IBV. The results of 
the present study are similar to the ones quoted 
above, the mean difference in SGRQ was –12.8; p 
< 0.001. In this study for the first time an attempt 
to evaluate 3 domains of SGRQ before and after 
treatment with intrabronchial valves was made. 
A significant improvement after the treatment in 
all three domains of SGRQ was proven and they 
amount to respectively: “symptoms” — –8.5; p < 
0.001, “activity” — –13.9; p < 0.001, “influence on 
life” — –13.5; p < 0.002. In the examined group 
the treatment with IBV significantly reduced the 
frequency of such symptoms as: cough, expecto-
rating, breathlessness, and wheezes from most to 
just a few days of the week. After the treatment 
with IBV a significant improvement based on 
the results of the domain “activity” SGRQ was 
achieved only in the range of low (basic) activity, 
such as: calm sitting or lying, washing and dress-
ing, walking around the house and on flat terrain. 
The treatment with IBV did not influence high 
activity, such as: going upstairs or uphill and exer-
cising. Despite the used treatment 60% of patients 
regarded their disease as their biggest problem.
The study has some important limitations 
that must be listed. It was conducted as a sin-
gle-centre study with a relatively small group of 
20 patients. The follow-up period was relatively 
short (only 3 months), requires further observa-
tions, including 2 to 5 year survival. In this study 
the interlobar septum integrity was assessed by 
the analysis of high resolution computed to-
mography (HRCT) [23].The measurement of the 
collateral ventilation by use of Chartis Pulmonary 
Assessment System was not available [24].
Conclusions
The presented study revealed the significant 
improvement of the quality of life measured by 
SGRQ after the IBV treatment for heterogeneous 
emphysema.
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After this study the significant improvement 
of all domains of SGRQ: symptoms, activity and 
influence on life was observed for the first time.
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